drugset / Trial / NCT02194127

Efficacy and Tolerability of a Bilberry Extract in Volunteers With Impaired Twilight and Night Vision

NCT02194127 ↗

Phase 2 Completed 195 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to determine the efficacy of Anthocyan to improve impaired twilight and night vision and to test its tolerability and safety.

Timeline

Start
1998-11
Primary completion
1999-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Anthocyan Unknown 160 mg —

Indications

No indication recorded.